A Serbian physician has received a rare international award for his research into the cardiovascular effects of Ozempic and similar medications, findings presented at a conference in Los Angeles this week. Professor Dr. Vladimir Jakovljević of the Faculty of Medical Sciences in Kragujevac was honored with an Excellence Award in Cardiovascular Sciences, recognizing significant contributions to the field.
Dr. Jakovljević’s presentation focused on experimental studies examining semaglutide, the active ingredient in Ozempic and its impact on the cardiovascular system. Results from animal studies, subsequently published in a peer-reviewed scientific journal, suggest the drug may have notably positive effects on heart health. The research has sparked discussion among clinicians and researchers regarding potential broader metabolic and cardiovascular benefits beyond its original purpose in managing type 2 diabetes.
The award, according to Dr. Jakovljević, acknowledges the function of his entire research team and highlights the importance of international collaboration and mentorship in advancing cardiovascular science. He emphasized that building a globally respected research group requires sustained academic support and cooperative efforts.
While the findings have generated optimism, Dr. Jakovljević cautioned against the misuse of Ozempic, stressing it is designed for medical use in patients with impaired glucose regulation, not for cosmetic weight loss. He warned that prescribing the drug solely for weight reduction without a medical indication could be inappropriate and that lifestyle changes or less intensive therapies may be more suitable options in some cases. Treatment decisions, he insisted, should be guided by a physician and based on a patient’s metabolic health status.
The potential cardiovascular benefits of GLP-1 receptor agonists like Ozempic are believed to stem from several physiological processes, including improved blood glucose control, weight reduction, anti-inflammatory effects, and possible blood pressure improvements. However, Dr. Jakovljević noted that these mechanisms are still under investigation and that long-term human data are crucial for confirming cardiovascular protection.
Current medical consensus, as reflected in cardiology and endocrinology guidelines, emphasizes that Ozempic should primarily be used for diabetes or medically indicated obesity, and that its use requires careful monitoring by healthcare professionals. Benefits must be carefully weighed against potential side effects, and individual metabolic profiles should be considered when determining suitability.
Despite the growing popularity of Ozempic, some public claims have suggested increased mortality risk or psychological side effects, though Dr. Jakovljević underscored the need for controlled studies to interpret such reports accurately, rather than relying on isolated cases or speculation. He concluded that while the drug demonstrates promise, it should not be self-prescribed or used without medical supervision.
